Skip to main content

Table 2 Vancomycin dosage methods (Nā€‰=ā€‰13)

From: Discrepancy between perceptions and acceptance of clinical decision support Systems: implementation of artificial intelligence for vancomycin dosing

Question

n (%)

Q5. Assuming you have an average census for patients newly started on vancomycin during your shift, on how many occasions do you review or re-review their vancomycin regimens (across all of these new starts)?

ā€ƒ0ā€“5 times

10 (77)

ā€ƒ6ā€“10 times

3 (23)

Q6. Assuming you have an average census for patients stabilized on vancomycin prior to your shift, on how many occasions do you review or re-review their vancomycin regimens (across all of these treated patients)?

ā€ƒ0ā€“5 times

13 (100)

Q7. How long does it take you to determine a dose of vancomycin for a new patient?

ā€ƒ0ā€“10 min

8 (62)

ā€ƒ11ā€“20 min

5 (38)

Q8. How long does it take you to review and, if appropriate, revise a regimen for the patients who are already on vancomycin therapy?

ā€ƒ0ā€“5 min

2 (16)

ā€ƒ5ā€“10 min

10 (76)

ā€ƒ11ā€“15 min

1 (8)

Q9. What percentage of the time do you need to change the dose entered by the ordering provider?

ā€ƒā€‰<ā€‰70%

2 (15)

ā€ƒ70%-80%

8 (62)

ā€ƒ81%-90%

2 (15)

ā€ƒā€‰>ā€‰90%

1 (8)

Q10. Which formula do you use to dose vancomycin?

ā€ƒCrCI, by Cockroft-Gault

9 (69)

ā€ƒeGFRCr, by MDRD or CKD-EPI

1 (8)

ā€ƒeGFRCr-CysC, by CKD-EPI

2 (15)

ā€ƒOther

1 (8)

  1. CrCI Creatinine Clearance, eGFR Estimated glomerular filtration rate, MDRD Modification of Diet in Renal Disease, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration